Breast Cancer

FDA Approves Test To Determine High Recurrence Risk In Breast Cancer Patients – TOP2A Gene FISH Test

FDA Approves Test To Determine High Recurrence Risk In Breast Cancer Patients – TOP2A Gene FISH Test

Fish Test

(Best Syndication) On Monday the U.S. Food and Drug Administration (FDA) announced the approval of a genetic test to help determine the tumor recurrence risk and long-term survival for patients with relatively high-risk breast cancer. The test uses fluorescent probes to highlight sections of DNA to determine gene or chromosome abnormalities.

The technology is known as FISH (fluorescent in situ hybridization). The FISH test is a cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes. The florescent probes bind parts of the chromosome which show a high degree of sequence similarity. Using microscopy, lab technicians can find out where the fluorescent probe bound to the chromosome.

Health Insurance And Screening Saves Lives – American Cancer Society Reports Death From Prostate Breast Colon Cancers Reduced

Health Insurance And Screening Saves Lives – American Cancer Society Reports Death From Prostate Breast Colon Cancers Reduced Among Insured

(Best Syndication) It may seem self evident, but a new study confirms that people without health insurance are less likely to receive screening and are more likely to be diagnosed at a later stage for cancer. This leads to worse outcomes and a lower survival rate.

The American Cancer Society released the results of their study on Thursday. The society used data collected from the National Cancer Database which is compiled from hospitals and paid for by the American College of Surgeons and the American Cancer Society.

Researcher Talk About Tamoxifen And Herceptin At the San Antonio Breast Cancer Symposium – HER2+ and Gene Test Chemotherapy

Researcher Talk About Tamoxifen And Herceptin At the San Antonio Breast Cancer Symposium – HER2+ and Gene Test Chemotherapy

Stock Photo

(Best Syndication) There is some important news coming from the 30th annual San Antonio Breast Cancer Symposium this year. Researchers from Loyola University Medical Center in Maywood report that a gene test can help doctors determine the need for chemotherapy, and researchers from the Mayo Clinic say that Herceptin helps women with HER2+ type of breast cancer irrespective of whether patients have extra copies of chromosome 17.

The Loyola researchers say that clinical trials found that some women can be spared the debilitating side-effects of chemotherapy. The research is leading to better individualized treatment for breast cancer. They compared recurrence rates for patients after 10 years.

Genetic Breakthrough in Breast Cancer Research – BRCA1 Gene Mutation Prevents Repair Of PTEN Gene – Drug Trials In Progress

Genetic Breakthrough in Breast Cancer Research – BRCA1 Gene Mutation Prevents Repair Of PTEN Gene – Drug Trials In Progress

See Image Below

(Best Syndication) Researchers believe they know why the mutation in the BRCA1 gene leads to breast cancer in some people. A worldwide investigation has led to the conclusion that the mutation knocks out the powerful tumor suppressor gene known as PTEN.

For 10 years researchers have been trying to figure out how the BRCA1 gene was related to breast cancer. In 1997 Ramon Parsons, M.D., Ph.D., the Avon Foundation Professor of Medicine and Pathology at Columbia University College of Physicians and Surgeons led one of two teams that identified the PTEN, one of the most important tumor suppressor genes altered in breast cancer.

Link Between Night Shift and Cancer – Workers Of Swing And Graveyard Shifts Higher Risk For Prostate and Breast Cancers

Link Between Night Shift and Cancer – Workers Of Swing And Graveyard Shifts Higher Risk For Prostate and Breast Cancers

Stock Photo

(Best Syndication) Researchers in Europe have presented more evidence that suggests that people who work the night shift are at a higher risk for developing cancer. The exact relationship is not yet clear, but the unusual results may have some merit. Previous research has shown higher rates for both breast and prostate cancer in night and graveyard shift employees.

The scientists believe that the lack of sunlight may disrupt the natural circadian rhythm which is the body's biological clock. The higher rate could be due to the creation of melatonin. Melatonin is a hormone which can suppress tumor development and is normally produced at night. More Below:

Syndicate content
Share/Save/Bookmark

      

Post to Facebook

Important: The material on Best Syndication is for informational purposes only and is not meant to be advice. Authors may have or will receive monetary compensation from the company's product/s mentioned. You should always seek professional advice before making any legal, financial or medical decisions and this website cannot substitute or replace any trained professional consultation.
Use of this site means that you agree to our TERMS OF SERVICE

Advertise On This Site
Copyright © 2006-2015 By Best Syndication All Rights Reserved